Comparative Pharmacology
Head-to-head clinical analysis: REPAGLINIDE versus STARLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REPAGLINIDE versus STARLIX.
REPAGLINIDE vs STARLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Repaglinide is a meglitinide analog that lowers blood glucose by stimulating insulin secretion from pancreatic beta cells. It binds to the sulfonylurea receptor (SUR) on the ATP-sensitive potassium channel (K-ATP channel), closing the channel and causing membrane depolarization, leading to calcium influx and exocytosis of insulin-containing granules.
STARLIX (nateglinide) is an oral antidiabetic agent that stimulates insulin secretion from the pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channels, causing depolarization, calcium influx, and exocytosis of insulin. It acts rapidly and has a short duration of action, primarily affecting postprandial glucose levels.
0.5-4 mg orally within 30 minutes before each meal (2-4 times daily). Maximum single dose: 4 mg; maximum total daily dose: 16 mg.
120 mg orally three times daily, taken 1 to 30 minutes before meals.
None Documented
None Documented
Clinical Note
moderateRepaglinide + Gatifloxacin
"Repaglinide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateRepaglinide + Rosoxacin
"Repaglinide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateRepaglinide + Levofloxacin
"Repaglinide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateRepaglinide + Trovafloxacin
"Repaglinide may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 1 hour (range 0.5–1.5 hours). This short half-life supports its use for prandial glucose control, with minimal risk of prolonged hypoglycemia.
1-1.5 hours; short half-life supports preprandial dosing to control postprandial hyperglycemia; no accumulation with repeated dosing.
Approximately 90% of the absorbed dose is excreted in the feces via bile (as metabolites and unchanged drug), and about 8% is excreted in the urine. Renal elimination of unchanged drug is negligible (<0.1%).
Primarily hepatic metabolism via CYP2C9 and CYP3A4; ~92% excreted in feces as metabolites, ~8% in urine as metabolites; less than 1% excreted unchanged.
Category C
Category C
Meglitinide Antidiabetic
Meglitinide Antidiabetic